Key result
Valsartan significantly increased circulating adiponectin levels and decreased mean blood pressure, but did not change insulin sensitivity in patients with type 2 diabetes and hypertension.
Why the study?
Does valsartan improve adiponectin levels and insulin sensitivity in patients with type 2 diabetes mellitus and mild-to-moderate hypertension?
Does valsartan improve adiponectin levels and insulin sensitivity in patients with type 2 diabetes mellitus and mild-to-moderate hypertension?
Valsartan increases adiponectin levels and lowers blood pressure but does not improve insulin sensitivity in patients with type 2 diabetes and hypertension.
Valsartan was associated with higher adiponectin and lower BP without insulin-sensitivity change; leaves open metabolic or outcome benefits in T2DM hypertension.
Evaluating increasing circulating adiponectin levels is becoming an important strategy in the prevention of diabetes mellitus and cardiovascular events. This study was designed to investigate the effect of the angiotensin II receptor blocker valsartan on blood adiponectin levels and insulin sensitivity in patients with type 2 diabetes and mild-to-moderate hypertension. A total of 91 Korean patients were treated with 80 mg/day valsartan for 4 weeks followed by 160 mg/day for a further 8 weeks. Blood pressure, adiponectin levels and metabolic parameters were measured before and after treatment. The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as an insulin sensitivity index. Valsartan significantly decreased mean blood pressure and increased circulating adiponectin levels. There were no differences in metabolic parameters, including HOMA-IR, glycosylated haemoglobin and lipid levels before and after treatment. These results indicated that valsartan increases circulating adiponectin levels, but does not change insulin sensitivity in patients with type 2 diabetes and mild-to-moderate hypertension.
No takes yet. Share an insight, caveat, or question.
Son et al. (2010) studied Type 2 diabetes mellitus and mild-to-moderate hypertension (n=91). Valsartan vs. Baseline was evaluated on Blood adiponectin levels and insulin sensitivity (HOMA-IR). Valsartan significantly increased circulating adiponectin levels and decreased mean blood pressure, but did not change insulin sensitivity in patients with type 2 diabetes and hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: